Please login to the form below

Not currently logged in
Email:
Password:

Rapidscan/GE Healthcare distribution deal

Rapidscan choses GE Healthcare to distribute coronary artery disease treatment in the UK and Germany

Rapidscan Pharma Solutions EU (RPS) has come to an agreement with GE Healthcare to promote and distribute Rapiscan (regadenoson) in the UK and Germany.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).

Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication. 

Stephen Lightfoot, global MI-SPECT segment leader, Medical Diagnostics, GE Healthcare, said: "The opportunity to launch Rapiscan with Rapidscan Pharma Solutions EU leverages the expertise and unique capabilities of both organisations - to bring an important product used for the diagnosis of coronary artery disease to the UK and German marketplace."  

Regadenoson was launched in the US in 2008 following clinical trials of more than 2,000 patients with known or suspected CAD.

12th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...
White paper: The impact of COVID-19 on chronic disease management
...

Infographics